

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization International Bureau



(43) International Publication Date
16 June 2005 (16.06.2005)

PCT

(10) International Publication Number
WO 2005/054418 A1

(51) International Patent Classification⁷: C11D 3/00,
1/722, A61L 2/18

GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(21) International Application Number:
PCT/US2004/039102

(22) International Filing Date:
22 November 2004 (22.11.2004)

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
10/724,679 1 December 2003 (01.12.2003) US

Declaration under Rule 4.17:

— as to the identity of the inventor (Rule 4.17(i)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



WO 2005/054418 A1

(54) Title: NONIONIC SURFACTANT CONTAINING COMPOSITIONS FOR CLEANING CONTACT LENSES

(57) Abstract: Compositions and methods for cleaning contact lenses employing one or more nonionic polyether surfactants having a HLB of less than 12 in an amount effective to reduce the amount of lipids on the contact lenses, thus rendering the contact lenses easier to clean. Additionally, by soaking contact lenses in the composition prior to inserting the lens on the eye, the compositions provide a prophylactic effect in preventing lipid deposition while the contact lens is worn.

WO 2005/054418

PCT/US2004/039102

NONIONIC SURFACTANT CONTAINING COMPOSITIONS FOR CLEANING CONTACT LENSES

Field of the Invention:

The present invention relates to compositions and methods for cleaning and disinfecting contact lenses. Compositions of the present invention are particularly effective in the removal of lipid deposits from the surfaces of contact lenses, thus rendering the contact lenses more comfortable for the contact lens wearer. Additionally, the subject compositions provide a prophylactic effect in preventing lipid deposits from forming on a contact lens having been soaked in the composition prior to the lens being worn.

Background of the Invention:

Conventionally, contact lenses have been classified into water-nonabsorptive contact lenses and water-absorptive contact lenses, and classified into hard contact lenses and soft contact lenses. Both hard and soft contact lenses may develop deposits or a stain of lipids derived from tears while the lens is worn in the eye. Such lipid stains may cause a deterioration in the comfort of a lens during wear or cause eye problems such as blurred eyesight or congestion of the cornea. Accordingly, it is essential to apply a cleaning treatment to a contact lens in order to safely and comfortably use contact lenses every day.

WO 2005/054418

PCT/US2004/039102

To effectively clean contact lenses, solutions formulated for cleaning contact lenses having cleaning or removal effect over one or more stains are typically used. Solutions formulated for cleaning contact lenses may include therein a surfactant useful as a cleaning component. Contact lens cleaning solutions incorporating nonionic surfactants such as a polyoxyalkylene block copolymer such as a polyoxyethylene-polyoxypropylene block copolymer or a derivative thereof are known.

However, cleaning solutions for contact lenses containing nonionic surfactants may risk causing eye irritation. Great importance is attached to the safety and comfort of lens care solutions, thus requiring the concentration of cleaning surfactants, if any in the solution, to be maintained as low as possible. Experience shows that conventional cleaning solutions for contact lenses containing cleaning surfactants at low concentrations to avoid eye discomfort or irritation, lack adequate cleaning power or lipid-solubilizing power. As a result, cleaning treatments of contact lenses using a low concentration surfactant cleaning solution, tend to allow lipid stains to remain and accumulate on the contact lens, potentially being harmful to the eye.

U.S. Patent Number 5,500,144 (Potini et al.), discloses compositions for the care of contact lenses including a silicone polymer containing an alkyleneoxide side chain. Included in the silicone polymer compositions are nonionic surface active agents having good cleaning activity, such as polyoxyethylene, polyoxypropylene block copolymers having hydrophilic/lipophilic balances (HLBs) of generally about 12 to about 18, as

WO 2005/054418

PCT/US2004/039102

opposed to other poloxamers that may also be employed in the compositions as primary cleaning agents having HLBs of at least about 18.

U.S. Patent Number 6,417,144 (Tsuzuki et al.), discloses a solution for contact lenses comprising the combination of an amino acid type cationic surfactant and at least one nonionic surfactant with an HLB above 18 whereby cleaning powers are synergistically increased over the use of either an amino acid type cationic surfactant or a nonionic surfactant independently.

As mentioned above, nonionic surfactants are well known in the art of contact lens cleaning. However independent use of nonionic surfactants for cleaning contact lenses appear to have considerable limitations in cleaning effectiveness at low concentrations and are known to potentially cause ocular irritation at higher concentrations. Accordingly, it would be desirable to find a contact lens cleaning solution effective in removing lipid stains without causing ocular irritation.

Summary of the Invention:

The present invention provides compositions that include an effective amount of a nonionic polyether surfactant having a hydrophilic/lipophilic balance (HLB) less than 12 for removing, reducing and/or preventing lipid deposits on contact lenses. Also, methods for removing lipid deposits from surfaces of contact lenses and for preventing or reducing the amount of such deposits thereon are provided. One method of the present invention comprises soaking a contact lens in an aqueous composition comprising a nonionic

WO 2005/054418

PCT/US2004/039102

polyether surfactant having a HLB less than 12, in an amount effective to reduce the formation of lipid deposits on the contact lens.

Another method of the present invention comprises soaking a contact lens in an aqueous composition comprising a nonionic polyether surfactant having a HLB less than 12 in an amount effective to remove lipid deposits from surfaces of the contact lens. According to various preferred embodiments, lipid deposits can be removed from surfaces of a contact lens without manual rubbing of the lens, for example, by rinsing.

Still another method of the present invention comprises preventing deposition of lipids on a contact lens while worn on the eye. This method comprises soaking the contact lens in an aqueous composition, and inserting the contact lens in the eye without rinsing the composition from the contact lens, or instilling one or more drops of the composition in the eye while wearing the contact lens, wherein the composition comprises a nonionic polyether surfactant having a HLB less than 12, in an amount effective to prevent deposition of lipids on a contact lens while worn in the eye.

Brief Description of the Drawings:

FIGURE 1 is a graph of lipid cleaning (absorbance at 485 nm) vs. concentration of nonionic polyether surfactant; and

FIGURE 2 is a graph illustrating the effect of solution volume on the lipid cleaning efficacy.

WO 2005/054418

PCT/US2004/039102

Detailed Description of the Invention:

Compositions of the present invention may be used with all contact lenses such as conventional hard, soft, rigid and soft gas permeable, and silicone (including both hydrogel and non-hydrogel) lenses, but is preferably employed with soft hydrogel lenses. Such lenses are commonly prepared from hydrophilic monomers such as 2-hydroxyethyl (meth)acrylate, N-vinylpyrrolidone, glycerol (meth)acrylate, and (meth)acrylic acid. In the case of silicone hydrogel lenses, a silicone-containing monomer is copolymerized with at least one hydrophilic monomer. Such lenses absorb significant amounts of water, typically from 10 to 80 percent by weight, and especially 20 to 70 percent water.

Compositions employed in this invention are aqueous solutions. The compositions include, as an essential component, one or more nonionic polyether surfactants. Suitable nonionic polyether surfactants for use in compositions of the present invention include for example but are not limited to Pluronic P123TM (BASF, Mount Olive, New Jersey) having a HLB of 8, Pluronic L42TM (BASF) having a HLB of 8, Pluronic L62TM (BASF) having a HLB of 7, Pluronic L72TM (BASF) having a HLB of 7, Pluronic L92TM (BASF) having a HLB of 6, Pluronic P103TM (BASF) having a HLB of 9, Pluronic R 12R3TM (BASF) having a HLB of 7, Pluronic R 17R1TM (BASF) having a HLB of 3, Pluronic R 17R2TM (BASF) having a HLB of 6, Pluronic R 31R1TM (BASF) having a HLB of 1, Pluronic R 31R2TM (BASF) having a HLB of 2, Pluronic R 31R4TM (BASF) having a HLB of 7, Tetronic 701TM (BASF) having a HLB of 3, Tetronic 702TM (BASF) having a HLB of 7, Tetronic 901TM (BASF) having a HLB of 3, Tetronic 1101TM (BASF) having a HLB of 2, Tetronic 1102TM (BASF) having a HLB of 6,

WO 2005/054418

PCT/US2004/039102

Tetronic 1301TM (BASF) having a HLB of 2, Tetronic 1302TM (BASF) having a HLB of 6, Tetronic 1501TM (BASF) having a HLB of 1, Tetronic 1502TM (BASF) having a HLB of 5, Tetronic R 50R1TM (BASF) having a HLB of 3, Tetronic R 50R4TM (BASF) having a HLB of 9, Tetronic R 70R1TM (BASF) having a HLB of 3, Tetronic R 70R2TM (BASF) having a HLB of 5, Tetronic R 70R4TM (BASF) having a HLB of 8, Tetronic R 90R1TM (BASF) having a HLB of 2, Tetronic R 90R4TM (BASF) having a HLB of 7, Tetronic R 110R1TM (BASF) having a HLB of 2, Tetronic R 110R2TM (BASF) having a HLB of 4, Tetronic R 110R7TM (BASF) having a HLB of 10, Tetronic R 130R1TM (BASF) having a HLB of 1, Tetronic R 130R2TM (BASF) having a HLB of 3, Tetronic R 150R1TM (BASF) having a HLB of 1, Tetronic R 150R4TM (BASF) having a HLB of 5 and Tetronic R 150R8TM (BASF) having a HLB of 11,

Relatively low HLB values less than 12 indicate a higher affinity for both hydrophobic molecules and/or surfaces, such as lipids and hydrophilic molecules. Relatively low HLB nonionic polyether surfactants have been found to significantly decrease lipid affinity to the surface of contact lenses, and are effective in removing lipids from the surface of contact lenses without mechanical or digital cleaning. Such nonionic polyether surfactants are preferably employed in compositions of the present invention in amounts ranging from about 0.1 to about 6.0 weight percent, more preferably from about 0.2 to about 5.0 weight percent to achieve cleaning efficacy.

According to various preferred embodiments of the present invention, the subject compositions are likewise suitable for disinfecting a contact lens soaked thereln. In addition to water, it is preferred that the subject

WO 2005/054418

PCT/US2004/039102

compositions also include at least one antimicrobial agent, especially a non-oxidative antimicrobial agent that derives its antimicrobial activity through a chemical or physicochemical interaction with organisms. So that the contact lenses treated with the composition may be instilled directly in the eye, i.e., without rinsing the contact lens with a separate composition, the antimicrobial agent needs to be an ophthalmically acceptable antimicrobial agent.

Suitable antimicrobial agents for use in the present invention include quaternary ammonium salts which do not include significant hydrophobic portions, e.g., alkyl chains comprising more than six carbon atoms. Suitable quaternary ammonium salts for use in the present invention include for example but are not limited to poly[(dimethylaminio)-2-butene-1,4-diyl chloride] and [4-tris(2-hydroxyethyl) ammonio]-2-butenyl- ω -[tris(2-hydroxyethyl)ammonio] dichloride (Chemical Abstracts Registry Number 75345-27-6) generally available as Polyquaternium 1 (Onyx Corporation, Montpelier, Vermont). Also suitable are biguanides and their salts, such as 1,1'-hexamethylene-bis[5-(2-ethylhexyl)biguanide] (Alexidine) and poly(hexamethylene biguanide) (PHMB) available from ICI Americas, Inc., Wilmington Delaware under the trade name Cosmocil CQ, benzalkonium chloride (BAK) and sorbic acid.

One or more antimicrobial agents are present in the subject compositions in an amount effective for disinfecting a contact lens, as found in conventional lens soaking and disinfecting solutions. Preferably, the antimicrobial agent will be used in a disinfecting amount or an amount from about 0.0001 to about 0.5 weight percent by volume. A disinfecting amount of an antimicrobial agent is an amount that will at least partially reduce the microorganism population in the

WO 2005/054418

PCT/US2004/039102

formulations employed. Preferably, a disinfecting amount is that which will reduce the microbial burden by two log orders in four hours and more preferably by one log order in one hour. Most preferably, a disinfecting amount is an amount that will eliminate the microbial burden on a contact lens when used in the regimen for the recommended soaking time (FDA Chemical Disinfection Efficacy Test – July, 1985 Contact Lens Solution Draft Guidelines). Typically, such agents are present in concentrations ranging from about 0.00001 to about 0.5 weight percent based on volume (w/v), and more preferably, from about 0.00003 to about 0.05 weight percent.

Compositions of the present invention may also contain various other components including for example but not limited to one or more chelating and/or sequestering agents, one or more osmolarity adjusting agents, one or more surfactants, one or more buffering agents and/or one or more wetting agents.

Chelating agents, also referred to as sequestering agents, are frequently employed in conjunction with an antimicrobial agent. These agents bind heavy metal ions, which might otherwise react with the lens and/or protein deposits and collect on the lens. Chelating agents are well known in the art, and examples of preferred chelating agents include ethylenediaminetetraacetic acid (EDTA) and its salts, especially disodium EDTA. Such agents are normally employed in amounts from about 0.01 to about 2.0 weight percent, more preferably from about 0.01 to about 0.3 weight percent. Other suitable sequestering agents include gluconic acid, citric acid, tartaric acid and their salts, e.g., sodium salts.

WO 2005/054418

PCT/US2004/039102

Compositions of the present invention may be designed for a variety of osmolarities, but it is preferred that the compositions are iso-osmotic with respect to eye fluids. Specifically, it is preferred that the compositions have an osmotic value of less than about 350 mOsm/kg, more preferably from about 175 to about 330 mOsm/kg, and most preferably from about 260 to about 310 mOsm/Kg. One or more osmolarity adjusting agents may be employed in the composition to obtain the desired final osmolarity. Examples of suitable osmolarity adjusting agents include, but are not limited to sodium and potassium chloride, monosaccharides such as dextrose, calcium and magnesium chloride, and low molecular weight polyols such as glycerin and propylene glycol. Typically, these agents are used individually in amounts ranging from about 0.01 to 5 weight percent and preferably, from about 0.1 to about 2 weight percent.

Compositions of the present invention have an ophthalmically compatible pH, which generally will range between about 6 to about 8, and more preferably between 6.5 to 7.8, and most preferably about 7 to 7.5. One or more conventional buffers may be employed to obtain the desired pH value. Suitable buffers include for example but are not limited to borate buffers based on boric acid and/or sodium borate, phosphate buffers based on Na_2HPO_4 , NaH_2PO_4 and/or KH_2PO_4 , citrate buffers based on sodium or potassium citrate and/or citric acid, sodium bicarbonate, aminoalcohol buffers and combinations thereof. Generally, buffers will be used in amounts ranging from about 0.05 to about 2.5 weight percent, and preferably, from about 0.1 to about 1.5 weight percent.

The subject compositions may likewise include a wetting agent, to facilitate the composition wetting the surface of a contact lens. Within the art,

WO 2005/054418

PCT/US2004/039102

the term "humectant" is also commonly used to describe these materials. A first class of wetting agents are polymer wetting agents. Examples of suitable wetting agents include for example but are not limited to poly(vinyl alcohol) (PVA), poly(N-vinylpyrrolidone) (PVP), cellulose derivatives and poly(ethylene glycol). Cellulose derivatives and PVA may be used to also increase viscosity of the composition, and offer this advantage if desired. Specific cellulose derivatives include for example but are not limited to hydroxypropyl methyl cellulose, carboxymethyl cellulose, methyl cellulose, hydroxyethyl cellulose, and cationic cellulose derivatives. As disclosed in U.S. Patent Number 6,274,133, cationic cellulosic polymers also help prevent accumulation of lipids and proteins on a hydrophilic lens surface. Such cationic cellulosic polymers include for example but are not limited to water soluble polymers commercially available under the CTFA (Cosmetic, Toiletry, and Fragrance Association) designation Polyquaternium-10, including the cationic cellulosic polymers available under the trade name UCARE® Polymers from Amerchol Corp., Edison, New Jersey. Generally, these cationic cellulose polymers contain quaternized N,N-dimethylamino groups along the cellulosic polymer chain.

Another suitable class of wetting agents is non-polymeric wetting agents. Examples include glycerin, propylene glycol, and other non-polymeric diols and glycols.

The specific quantities of wetting agents used in the present invention will vary depending upon the application. However, the wetting agents will typically be included in an amount from about 0.01 to about 5 weight percent, preferably from about 0.1 to about 2 weight percent.

WO 2005/054418

PCT/US2004/039102

It will be understood that some constituents possess more than one functional attribute. For example, cellulose derivatives are suitable polymeric wetting agents, but are also referred to as "viscosity increasing agents" to increase viscosity of the composition if desired. Glycerin is a suitable non-polymeric wetting agent but is also may contribute to adjusting tonicity.

Compositions of the present invention may also include at least one ophthalmically acceptable surfactant, which may be either cationic, anionic, nonionic or amphoteric. Preferred surfactants are amphoteric or nonionic surfactants. The surfactant should be soluble in the aqueous solution and non-irritating to eye tissues. The surfactant serves mainly to facilitate removal of non-proteinaceous matter on the contact lens.

Many nonionic surfactants comprise one or more chains or polymeric components having oxyalkylene (-O-R-) repeats units wherein R has 2 to 6 carbon atoms. Representative non-ionic surfactants comprise block polymers of two or more different kinds of oxyalkylene repeat units, which ratio of different repeat units determines the HLB of the surfactant. Typical HLB values for surfactants found to be suitable are in the range of 18 or above. Examples of such poloxamers are polyoxyethylene, polyoxypropylene block copolymers available under the trade name Pluronic (BASF). Poloxamines are ethylene diamine adducts of such polyoxyethylene, polyoxypropylene block copolymers available under the trade name Tetronic (BASF), including for example poloxamine 1107 (Tetronic 1107) having a molecular weight from about 7,500 to about 27,000 wherein at least 40 weight percent of said adduct is poly(oxyethylene) having a HLB of 24. Other non-ionic surfactants include for

WO 2005/054418

PCT/US2004/039102

example polyethylene glycol esters of fatty acids, e.g. coconut, polysorbate, polyoxyethylene or polyoxypropylene ethers of higher alkanes (C₁₂-C₁₈), polysorbate 20 available under the trade name Tween® 20 (ICI Americas, Inc., Wilmington, Delaware), polyoxyethylene (23) lauryl ether available under the trade name Brij® 35 (ICI Americas, Inc.), polyoxyethyene (40) stearate available under the trade name Myrij® 52 (ICI Americas, Inc.), polyoxyethylene (25) propylene glycol stearate available under the trade name Atlas® G 2612 (ICI Americas, Inc.).

Another useful class of cleaning agents are the hydroxyalkylphosphonates, such as those disclosed in U.S. Patent Number 5,858,937 (Richards et al.), and available under the trade name Dequest® (Monsanto Co., St. Louis, Missouri).

Amphoteric surfactants suitable for use in a composition according to the present invention include materials of the type are offered commercially under the trade name Miranol™ (Noveon, Inc., Cleveland, Ohio). Another useful class of amphoteric surfactants is exemplified by cocoamidopropyl betaine, commercially available from various sources.

Various other ionic as well as amphoteric and anionic surfactants suitable for in the invention can be readily ascertained, in view of the foregoing description, from *McCutcheon's Detergents and Emulsifiers*, North American Edition, McCutcheon Division, MC Publishing Co., Glen Rock, NJ 07452 and the *CTFA International Cosmetic Ingredient Handbook*, Published by The Cosmetic, Toiletry, and Fragrance Association, Washington, D.C.

WO 2005/054418

PCT/US2004/039102

Preferably, the surfactants, when present, are employed in a total amount from about 0.01 to about 15 weight percent, preferably about 0.1 to about 9.0 weight percent, and most preferably about 0.1 to about 7.0 weight percent.

As an illustration of the present invention, several examples are provided below. These examples serve only to further illustrate aspects of the invention and should not be construed as limiting the invention.

EXAMPLE 1 – Preparation of Test Solutions:

Sample solutions for testing were prepared in accordance with the formulations set forth below in Table 1.

TABLE 1
TEST SOLUTIONS

Ingredients	%W/W	Test Solution				
		1	2	3	4	5
Pluronic P123		0.250	0.500	1.000	2.500	5.000
Tetronic 1107		1.00	1.00	1.00	1.00	1.00
Sodium Borate		0.09	0.09	0.09	0.09	0.09
Boric Acid		0.64	0.64	0.64	0.64	0.64
EDTA		0.11	0.11	0.11	0.11	0.11
PHMB (ppm)		1.0	1.0	1.0	1.0	1.0
Dequest 2016		0.03	0.03	0.03	0.03	0.03
Sodium Chloride		0.49	0.49	0.49	0.49	0.49
Purified Water		Q.S. to 100 gm				

WO 2005/054418

PCT/US2004/039102

EXAMPLE 2 – Preparation of Artificial Tears for Lipid Cleaning (Model 1 Hands-Off Regimen):

Artificial tears for use in testing were prepared in accordance with the formulation set forth below in Table 2. The pH of the artificial tears was adjusted to 7.2 using 1 N HCl. Osmolarity = 320 mOsm/kg.

TABLE 2
Artificial Tears Formulation

<u>Ingredients</u>	<u>%W/W</u>
<u>Salts and Buffer</u>	
NaCl	0.7
KCl	0.2
NaHCO ₃	0.12
CaCO ₃	0.01
NaH ₂ PO ₄ H ₂ O	0.01
3-(N-morpholino)propanesulfonic acid	0.4
<u>Lipids</u>	
Palmitic acid methyl ester	0.25
Cholesterol	0.25
Squalene	0.25
<u>Proteins</u>	
MucIn	0.01
Lactoferrin	0.01
Human albumin serum	0.01
Lysozyme	0.25

WO 2005/054418

PCT/US2004/039102

EXAMPLE 3 – Preparation of Artificial Tears for Lipid Cleaning (Model 2**Hands-Off Regimen):**

Super sterol ester (9.9 gm) was heated slowly until it melted. After melting, 0.1 gm of Sudan I was added to form a 99:1 mixture. The same was then mixed until the solution was homogenous. Using a glass pipette, five drops of mixture were transferred into each 12 cm x 12 mm glass screw top test tube. The test tubes were visually checked to ensure that the volume at the bottom of each test tube were of about equal size and diameter. Each batch should accommodate 40 to 50 tubes.

After preparing the tubes, 5 mL of the test solution was placed into each prepared tube. The tubes were then placed in a rotary shaker for 24 hours on 150 revolutions per minute (rpm) and 25 °C. After cleaning, the absorbance (ABS) was measured at 485.5 nm.

EXAMPLE 4 – Lipid Cleaning Results from Model 2 Hands-Off Regimen:

The lipid cleaning results from the Model 2 Hands-Off Regimen using SureVue™ (Bausch & Lomb Incorporated, Rochester, New York) lenses are set forth below in Table 3 and illustrated in Figure 1.

WO 2005/054418

PCT/US2004/039102

TABLE 3**Model 2 Hands-Off Regimen using SureVue Contact Lenses**

<u>Test Solution</u>	<u>Average ABS (485.5 nm)</u>
1	0.198
2	0.376
3	0.620
4	1.376
5	1.675

EXAMPLE 5 – Effect of Solution Volumes on the Lipid Cleaning Efficacy
from Model 2 Hands-Off Regimen:

The effect of solution volumes on lipid cleaning efficacy from the Model 2 Hands-Off Regimen using SureVue™ lenses are set forth below in Table 4 and illustrated in Figure 2.

TABLE 4**Model 2 Hands-Off Regimen using SureVue Contact Lenses**

<u>Test Solution</u>	<u>Average Absorbance</u>
<u>Volume (mL)</u>	<u>(485.5 nm)</u>
2.0	0.883
4.0	0.918
6.0	1.086

WO 2005/054418

PCT/US2004/039102

EXAMPLE 6 – Lipid Cleaning Results from Model 1 Hands-Off Regimen:

The lipid cleaning results from the Model 1 Hands-Off Regimen using PureVision™ (Bausch & Lomb Incorporated) lenses are set forth below in Table 5.

TABLE 5**Model 1 Hands-Off Regimen using PureVision Contact Lenses**

<u>Test Solutions</u>	<u>Lipid Cleaning Efficacies (%)</u>
Control	70.5
Control + Pluronic P123	95.7

Compositions of the present invention may be used for soaking a contact lens whereby the aqueous composition comprises one or more nonionic polyether surfactants having a HLB less than 12 in an amount effective to reduce the formation of lipid deposits on the contact lens.

Compositions of the present invention may also be used for rinsing or soaking a contact lens whereby the aqueous composition comprises one or more nonionic polyether surfactants having a HLB less than 12 in an amount effective to remove lipid deposits from surfaces of the contact lens.

Still another method of using compositions of the present invention comprises preventing deposition of lipids on a contact lens while worn on the eye. This method comprises soaking the contact lens in an aqueous composition with one or more nonionic polyether surfactants having a HLB less than 12 present in an effective amount, and inserting the contact lens in the eye

WO 2005/054418

PCT/US2004/039102

without rinsing the composition from the contact lens, or instilling one or more drops of the composition in the eye while wearing the contact lens, to prevent deposition of lipids on a contact lens while worn in the eye.

Although various preferred embodiments have been illustrated, many other modifications and variations of the present invention are possible to the skilled practitioner. It is therefore understood that, within the scope of the claims, the present invention can be practiced other than as herein specifically described.

WO 2005/054418

PCT/US2004/039102

We claim:

1. Compositions for reducing the amount of lipid deposits on a contact lens comprising:
one or more nonionic polyether surfactants having a HLB less than 12 ; and
one or more antimicrobial agents.
2. The composition of claim 1 wherein said one or more nonionic polyether surfactants are selected from the group consisting of Pluronic P123TM, Pluronic L42TM, Pluronic L62TM, Pluronic L72TM, Pluronic L92TM, Pluronic P103TM, Pluronic R 12R3TM, Pluronic R 17R1TM, Pluronic R 17R2TM, Pluronic R 31R1TM Pluronic R 31R2TM, Pluronic R 31R4TM, Tetronic 701TM, Tetronic 702TM, Tetronic 901TM, Tetronic 1101TM, Tetronic 1102TM, Tetronic 1301TM, Tetronic 1302TM, Tetronic 1501TM, Tetronic 1502TM, Tetronic R 50R1TM, Tetronic R 50R4TM, Tetronic R 70R1TM, Tetronic R 70R2TM, Tetronic R 70R4TM, Tetronic R 90R1TM, Tetronic R 90R4TM, Tetronic R 110R1TM, Tetronic R 110R2TM, Tetronic R 110R7TM, Tetronic R 130R1TM, Tetronic R 130R2TM, Tetronic R 150R1TM, Tetronic R 150R4TM and Tetronic R 150R8TM.
3. The composition of claim 1, wherein the composition further comprises at least one member selected from the group consisting of a buffering

WO 2005/054418

PCT/US2004/039102

agent, a chelating agent, an osmolarity adjusting agent, and a surfactant having a HLB of 18 or above.

4. The composition of claim 1, wherein said one or more antimicrobial agents are present in an amount effective to disinfect a contact lens.
5. The composition of claim 1 wherein the composition comprises about 0.1 to about 6.0 weight percent of said nonionic polyether surfactant and about 0.05 to about 0.5 weight percent of said antimicrobial agent.
6. The composition of claim 1 wherein the composition further comprises a chelating agent and a buffering agent selected from the group consisting borate buffers, phosphate buffers and citrate buffers.
7. The composition of claim 6, wherein the composition comprises at least one member selected from the group consisting of poloxamer and poloxamine surfactants having HLB values of 18 or greater.
8. A method of preventing deposition of lipids and proteins on a contact lens while worn on the eye comprising:
soaking said contact lens in an aqueous composition with one or more nonionic polyether surfactants having a HLB less than 12 in an amount effective to prevent deposition of lipids on said lens while worn in an eye; and

WO 2005/054418

PCT/US2004/039102

inserting said contact lens in an eye with or without rinsing the composition from said contact lens.

9. A method of preventing deposition of lipids on a contact lens while worn on the eye comprising:

instilling an aqueous composition with one or more nonionic polyether surfactants having a HLB less than 12 in an amount effective to prevent deposition of lipids into an eye while a contact lens is worn in said eye.

10. A method of reducing the amount of lipid deposits on a contact lens comprising:

soaking a contact lens in an aqueous composition with an effective amount of one or more nonionic polyether surfactants having a HLB less than 12 to reduce the amount of lipid deposits on said contact lens.

11. A method of removing lipid deposits from surfaces of a contact lens comprising:

soaking a contact lens in an aqueous composition with one or more nonionic polyether surfactants having a HLB less than 12 in an amount effective to remove lipid deposits from surfaces of a contact lens; and

inserting said contact lens in an eye with or without rinsing said composition from said contact lens.

WO 2005/054418

PCT/US2004/039102

12. The method of claim 8, 9, 10 or 11 wherein the composition further comprises at least one member selected from the group consisting of an antimicrobial agent, a buffering agent, a chelating agent, an osmolarity adjusting agent, and a surfactant having a HLB value of 18 or greater.
13. The method of claim 8, 9, 10 or 11 wherein the composition further comprises an antimicrobial agent in an amount effective to disinfect the contact lens.
14. The method of claim 8, 9, 10 or 11 wherein the composition comprises about 0.05 to about 0.5 weight percent of said antimicrobial agent.
15. The method of claim 14 wherein the composition further comprises a chelating agent and a buffering agent selected from the group consisting borate buffers, phosphate buffers and citrate buffers.
16. The method of claim 14 wherein the composition further comprises a surfactant having a HLB value of 18 or greater.

WO 2005/054418

PCT/US2004/039102

17. The method of claim 14 wherein the composition comprises at least one member selected from the group consisting of poloxamer and poloxamine surfactants having a HLB value of 18 or greater.

18. A method of cleaning a contact lens comprising:
soaking the contact lens in an aqueous composition that
comprises one or more nonionic polyether surfactants having a HLB
less than 12 in an amount effective to remove or reduce the amount of
lipids on the contact lens; and
rinsing the contact lens to remove the lipids.

19. The method of claim 18 wherein the lipids are removed without
manual rubbing.

20. The method of claim 18 wherein the contact lens is rinsed with said
composition and then inserted directly into the eye.

21. The method of claim 18 wherein the composition includes an
antimicrobial agent and the contact lens is disinfected while soaked in the
aqueous composition.

22. The method of claim 18 wherein the antimicrobial agent is present
in an amount effective to disinfect the contact lens.

WO 2005/054418

PCT/US2004/039102

23. The method of claim 8, 9, 10, 11 or 18 wherein said one or more nonionic polyether surfactants are selected from the group consisting of Pluronic P123TM, Pluronic L42TM, Pluronic L62TM, Pluronic L72TM, Pluronic L92TM, Pluronic P103TM, Pluronic R 12R3TM, Pluronic R 17R1TM, Pluronic R 17R2TM, Pluronic R 31R1TM, Pluronic R 31R2TM, Pluronic R 31R4TM, Tetronic 701TM, Tetronic 702TM, Tetronic 901TM, Tetronic 1101TM, Tetronic 1102TM, Tetronic 1301TM, Tetronic 1302TM, Tetronic 1501TM, Tetronic 1502TM, Tetronic R 50R1TM, Tetronic R 50R4TM, Tetronic R 70R1TM, Tetronic R 70R2TM, Tetronic R 70R4TM, Tetronic R 90R1TM, Tetronic R 90R4TM, Tetronic R 110R1TM, Tetronic R 110R2TM, Tetronic R 110R7TM, Tetronic R 130R1TM, Tetronic R 130R2TM, Tetronic R 150R1TM, Tetronic R 150R4TM and Tetronic R 150R8TM.

WO 2005/054418

PCT/US2004/039102

1/2

**Lipid Cleaning VS P123
Concentrations
Model 1**




FIGURE 1

WO 2005/054418

2/2

PCT/US2004/039102

Effect of Solution Volume on the Lipid Cleaning Efficacy (P123, Model 2)




FIGURE 2

INTERNATIONAL SEARCH REPORT

Intern. application No
PCT. 04/039102

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 C11D3/00 C11D1/722 A61L2/18

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 C11D A61L

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the International search (name of data base and, where practical, search terms used)

EPO-Internal, PAJ, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 0 524 150 A (CIBA-GEIGY AG) 20 January 1993 (1993-01-20) page 3, line 14 - line 24; claims page 4, line 9 - page 5, line 3; examples	1-23
X	EP 0 439 429 A (CIBA-GEIGY AG) 31 July 1991 (1991-07-31) page 3, line 1 - line 4 page 3, line 45 - line 47; claims; examples page 4, line 10 - line 17	1-23
X	WO 95/01414 A (ALLERGAN, INC) 12 January 1995 (1995-01-12) page 3, line 1 - line 35; claims; examples 4,5 page 7, line 1 - line 12	1-23

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the International filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the International filing date but later than the priority date claimed

- *T* later document published after the International filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *&* document member of the same patent family

Date of the actual completion of the International search

4 March 2005

Date of mailing of the International search report

17/03/2005

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel: (+31-70) 340-2040, Tx: 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Hillebrecht, D

INTERNATIONAL SEARCH REPORT

International Application No
PCT/U...J4/039102

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 4 046 706 A (KREZANOSKI ET AL) 6 September 1977 (1977-09-06) column 1, line 5 - line 21; claims column 6, line 21 - line 65 -----	1-23
X	US 2003/119684 A1 (TSAO FU-PAO) 26 June 2003 (2003-06-26) paragraphs '0005!, '0013! - '0018!, '0022!, '0030!; claims -----	1-23
X	US 4 504 405 A (HOWES) 12 March 1985 (1985-03-12) column 1, line 13 - line 35; claims column 2, line 59 - column 3, line 18 -----	1-23
X	WO 02/26922 A (NOVARTIS-ERFINDUNGEN VERWALTUNGSGESELLSCHAFT MBH;) 4 April 2002 (2002-04-04) page 8, line 3 - line 34; claims -----	1-6, 10-15, 18,21-23
X	US 2002/141899 A1 (TSAO FU-PAO) 3 October 2002 (2002-10-03) paragraphs '0005!, '0012!, '0014!, '0015!, '0024!, '0028!, '0034!; claims -----	1-6, 10-15, 18,21-23
X	EP 0 255 041 A (HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN) 3 February 1988 (1988-02-03) example 4 -----	1,3-6, 10,13-15

INTERNATIONAL SEARCH REPORT

International Application No
PCT/GB04/039102

Patent document cited in search report	Publication date		Patent family member(s)	Publication date
EP 0524150	A 20-01-1993	US	5523012 A	04-06-1996
		AT	186648 T	15-12-1999
		AU	657773 B2	23-03-1995
		AU	2034792 A	21-01-1993
		CA	2074108 A1	20-01-1993
		DE	69230304 D1	23-12-1999
		DE	69230304 T2	21-12-2000
		EP	0524150 A1	20-01-1993
		FI	923281 A	20-01-1993
		IE	922337 A1	27-01-1993
		JP	5201816 A	10-08-1993
		NO	922823 A	20-01-1993
		NZ	243606 A	27-04-1995
		ZA	9205355 A	24-02-1993
EP 0439429	A 31-07-1991	US	5209865 A	11-05-1993
		AU	636698 B2	06-05-1993
		AU	6934491 A	01-08-1991
		CA	2034834 A1	26-07-1991
		EP	0439429 A2	31-07-1991
		IE	910257 A1	31-07-1991
		JP	4313721 A	05-11-1992
		PT	96552 A	15-10-1991
WO 9501414	A 12-01-1995	AU	7319394 A	24-01-1995
		EP	0724622 A1	07-08-1996
		JP	8512145 T	17-12-1996
		WO	9501414 A1	12-01-1995
US 4046706	A 06-09-1977	NONE		
US 2003119684	A1 26-06-2003	AU	2002352072 A1	10-06-2003
		CA	2464491 A1	30-05-2003
		WO	03043668 A2	30-05-2003
		EP	1448753 A2	25-08-2004
US 4504405	A 12-03-1985	GB	2090013 A ,B	30-06-1982
		AT	11869 T	15-03-1985
		AU	557730 B2	08-01-1987
		AU	7859981 A	24-06-1982
		CA	1180278 A1	01-01-1985
		DE	3169105 D1	28-03-1985
		EP	0055515 A2	07-07-1982
		JP	57132115 A	16-08-1982
		US	4438011 A	20-03-1984
		ZA	8108378 A	24-11-1982
		AT	17952 T	15-02-1986
		DE	3269093 D1	27-03-1986
		EP	0079185 A1	18-05-1983
WO 0226922	A 04-04-2002	AU	2356402 A	08-04-2002
		BR	0114241 A	07-10-2003
		CA	2418510 A1	04-04-2002
		CN	1466622 A	07-01-2004
		WO	0226922 A1	04-04-2002
		EP	1325100 A1	09-07-2003
		HU	0301155 A2	29-09-2003
		JP	2004509930 T	02-04-2004

INTERNATIONAL SEARCH REPORT

Internl	lication No
PCT, 2004/039102	

Patent document cited in search report	Publication date	Patent family member(s)			Publication date
WO 0226922	A	MX	PA03002780	A	28-07-2003
		NO	20031359	A	25-03-2003
		TW	524697	B	21-03-2003
		US	2002141899	A1	03-10-2002
		ZA	200300992	A	19-04-2004
US 2002141899	A1 03-10-2002	AU	2356402	A	08-04-2002
		BR	0114241	A	07-10-2003
		CA	2418510	A1	04-04-2002
		CN	1466622	A	07-01-2004
		WO	0226922	A1	04-04-2002
		EP	1325100	A1	09-07-2003
		HU	0301155	A2	29-09-2003
		JP	2004509930	T	02-04-2004
		MX	PA03002780	A	28-07-2003
		NO	20031359	A	25-03-2003
		TW	524697	B	21-03-2003
		ZA	200300992	A	19-04-2004
EP 0255041	A 03-02-1988	DE	3626082	A1	11-02-1988
		AT	62818	T	15-05-1991
		DE	3769540	D1	29-05-1991
		EP	0255041	A1	03-02-1988
		JP	1628662	C	20-12-1991
		JP	2041008	B	14-09-1990
		JP	63037313	A	18-02-1988
		US	4775424	A	04-10-1988

